We are live on ! Find out more
RG

Redmile Group Portfolio holdings

AUM $1.49B
1-Year Est. Return 208.7%
This Fund
S&P 500
This Quarter Est. Return
-13.65%
1 Year Est. Return
+208.7%
3 Year Est. Return
+777.5%
5 Year Est. Return
+1,114.43%
10 Year Est. Return
+23,630.52%
AUM
$2.62B
AUM Growth
-$585M
Cap. Flow
+$149M
Cap. Flow %
5.7%
Top 10 Hldgs %
51.83%
Holding
74
New
4
Increased
19
Reduced
26
Closed
3

Top Buys

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$86.5M
2
SGEN
Seagen Inc. Common Stock
SGEN
+$59.5M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$49.6M
4
MDVL
MedAvail Holdings, Inc. Common Stock
MDVL
+$24.8M
5
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$23.9M

Top Sells

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$41.9M
2
UNH icon
UnitedHealth
UNH
+$27.3M
3
LIVN icon
LivaNova
LIVN
+$24.6M
4
ICUI icon
ICU Medical
ICUI
+$21.6M
5
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 96.46%
2 Consumer Staples 2.55%
3 Industrials 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FATE icon
1
Fate Therapeutics
FATE
$291M
$321M 12.26%
12,957,222
– –
FOLD
2
DELISTED
Amicus Therapeutics
FOLD
$238M 9.09%
22,158,891
-170,495
-0.8% -$1.4M
SGEN
3
DELISTED
Seagen Inc. Common Stock
SGEN
$151M 5.77%
854,013
+412,739
+94% +$59.5M
ARGX icon
4
argenx
ARGX
$64B
$146M 5.58%
385,818
-130,125
-25% -$41.9M
KRYS icon
5
Krystal Biotech
KRYS
$10.4B
$125M 4.76%
1,898,545
+82,847
+5% +$5.15M
LIVN icon
6
LivaNova
LIVN
$4.43B
$101M 3.87%
1,623,762
-346,749
-18% -$24.6M
HZNP
7
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$72.8M 2.78%
+913,319
New +$86.5M
BEAM icon
8
Beam Therapeutics
BEAM
$3.03B
$71.6M 2.73%
1,849,887
+13,837
+0.8% +$550K
SKIN icon
9
SkinHealth Systems
SKIN
$89.1M
$66.7M 2.55%
5,186,348
-118,157
-2% -$1.58M
REPL icon
10
Replimune Group
REPL
$1.46B
$63.7M 2.43%
3,645,309
-46,003
-1% -$756K
IGMS
11
DELISTED
IGM Biosciences
IGMS
$60.1M 2.3%
3,334,355
– –
ADCT icon
12
ADC Therapeutics
ADCT
$146M
$59.7M 2.28%
7,512,029
+79,600
+1% +$753K
CLDX icon
13
Celldex Therapeutics
CLDX
$3.07B
$55.8M 2.13%
2,070,288
+24,019
+1% +$698K
CNC icon
14
Centene
CNC
$32B
$55.1M 2.1%
651,447
+2,610
+0.4% +$217K
KYMR icon
15
Kymera Therapeutics
KYMR
$9.82B
$51.3M 1.96%
2,607,130
-7,900
-0.3% -$185K
XENE icon
16
Xenon Pharmaceuticals
XENE
$5.81B
$49.9M 1.9%
+1,639,344
New +$49.6M
RGNX icon
17
Regenxbio
RGNX
$638M
$49.5M 1.89%
2,004,663
+27,740
+1% +$693K
ATRA icon
18
Atara Biotherapeutics
ATRA
$92.3M
$48.6M 1.86%
249,710
-126
-0.1% -$20.6K
IMGN
19
DELISTED
Immunogen Inc
IMGN
$41.1M 1.57%
9,141,045
-76,900
-0.8% -$334K
ELV icon
20
Elevance Health
ELV
$85.5B
$40.5M 1.55%
83,987
+825
+1% +$408K
SNCE
21
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
$39.8M 1.52%
990,412
– –
MDVL
22
DELISTED
MedAvail Holdings, Inc. Common Stock
MDVL
$38.5M 1.47%
503,855
+282,353
+127% +$24.8M
NRIX icon
23
Nurix Therapeutics
NRIX
$2.72B
$38.1M 1.45%
3,006,684
-12,100
-0.4% -$137K
RPTX
24
DELISTED
Repare Therapeutics
RPTX
$38.1M 1.45%
2,720,996
-12,000
-0.4% -$141K
ONEM
25
DELISTED
1Life Healthcare
ONEM
$35.5M 1.35%
4,521,825
+1,116,990
+33% +$9.6M
1
2 3

Similar funds

FCM
Fairholme Capital Management South Miami, Florida $1.49B AUM 28.35% 1-Year Est. Return
MM
Main Management San Francisco, California $1.49B AUM 22.28% 1-Year Est. Return
WA
WBH Advisory Baltimore, Maryland $1.49B AUM 20.41% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.49B AUM 32.81% 1-Year Est. Return
LCS
Levin Capital Strategies New York $1.49B AUM 30.44% 1-Year Est. Return
GAM
Gemmer Asset Management Walnut Creek, California $1.49B AUM 42.66% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $1.49B AUM 26.43% 1-Year Est. Return
PMG
ProVise Management Group Clearwater, Florida $1.49B AUM 21.79% 1-Year Est. Return

Redmile Group's Q2 2022 Portfolio in Review

As of Q2 2022, Redmile Group held 74 positions worth $2.62B, down 18% from $3.2B the previous quarter. Its ten largest holdings account for 52% of the portfolio.

Redmile Group deployed $149M of net new capital in Q2 2022, opening 4 new positions and adding to 19 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 913,319 shares worth $72.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Consumer Staples and Industrials.

On the sell side, the largest reduction was argenx, an estimated $41.9M trimmed.

  • Redmile Group's largest Q2 2022 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 913,319 shares worth $72.8M.
  • Redmile Group added most to Seagen Inc. Common Stock in Q2 2022, an estimated $59.5M increase.
  • Redmile Group's biggest Q2 2022 reduction was argenx, cutting an estimated $41.9M.
  • Redmile Group fully exited UnitedHealth in Q2 2022, selling an estimated $27.3M.
  • Redmile Group's ten largest holdings make up 52% of its $2.62B portfolio in Q2 2022.
  • Redmile Group opened 4 new positions and closed 3 in Q2 2022.
  • Redmile Group's portfolio value fell 18% quarter-over-quarter to $2.62B.

Based on Redmile Group's 13F filing for Q2 2022, filed 15 Aug 2022.